CMV Prevention Drug Fast-Tracked by FDA Monthly Prescribing Reference Phase 2 clinical development of CMX001, for the prevention of CMV infection in adult hematopoietic stem cell transplant (HSCT) recipients, has been completed. Chimeric is planning on initiating SUPPRESS, a Phase 3 study of CMX001 for the prevention of ... Chimerix antiviral lands on FDA's fast track Chimerix receives FDA Fast Track designation for CMX001 to prevent CMV ... |
